Special Drug Use-results Survey for Long-term Use (Fostamatinib)
NCT06757257 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 149
Last updated 2025-01-03
Summary
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Conditions
- Chronic Idiopathic Thrombocytopenic Purpura
Interventions
- DRUG
-
fostamatinib
oral administration
Sponsors & Collaborators
-
Kissei Pharmaceutical Co., Ltd.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-29
- Primary Completion
- 2028-09-30
- Completion
- 2028-09-30
Countries
- Japan
More Related Trials
-
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
NCT06071520 ·Status: COMPLETED
-
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02077192 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
NCT04132050 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
NCT03363334 ·Status: NO_LONGER_AVAILABLE
-
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
NCT06287567 ·Status: COMPLETED ·Phase: PHASE2
-
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
NCT04543279 ·Status: TERMINATED ·Phase: PHASE2
-
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962 ·Status: RECRUITING ·Phase: PHASE2
-
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
NCT05093257 ·Status: UNKNOWN
-
Safety Study of AMG 531 in Japanese Subjects With ITP
NCT00305435 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
NCT02868060 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Exploratory Study of Golidocitinib in Adult Patients With ITP
NCT07196163 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
NCT05325593 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Zanubrutinib in Patients With ITP
NCT05279872 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP
NCT02338414 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
NCT06594146 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT02614846 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment of ITP With Rituximab and / or Accutane
NCT02757196 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
NCT06658834 ·Status: RECRUITING ·Phase: PHASE2
-
Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
NCT00861601 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
NCT07206823 ·Status: RECRUITING ·Phase: NA
-
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
NCT01652599 ·Status: COMPLETED ·Phase: PHASE2